Allergy Shots Treatment: The Disease-Modifying Immunotherapy Overview
Allergy shots treatment is subcutaneous immunotherapy (SCIT) — a 3-to-5-year course of weekly-to-monthly allergen-extract injections designed to induce immune tolerance. Cochrane SMD −0.73 for seasonal AR (51 RCTs); NNT 3 to prevent asthma deterioration; 0.1% systemic-reaction rate per visit. NOT indicated for chronic urticaria (use Xolair) or food allergy. 23.9% of patients never return for their first injection.
8 peer-reviewed sources
Allergy shots treatment is SCIT — 24-28 weekly build-up injections then monthly maintenance for 3-5 years, indicated for allergic rhinitis, asthma, and Hymenoptera venom allergy. Cochrane symptom SMD −0.73 across 51 RCTs. Not for chronic hives or food allergy.
The essentials
Allergy shots treatment — subcutaneous immunotherapy (SCIT) — is a 3-to-5-year course of weekly-to-monthly subcutaneous injections of allergen extracts designed to induce immune tolerance to specific IgE-sensitized allergens. It is the only FDA-recognized disease-modifying treatment for IgE-mediated allergic disease, codified in the US by Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034, AAAAI/ACAAI/JCAAI Practice Parameter Third Update). CMS LCD L36240 designates Cox 2011 PP3 as the operative coverage standard.
The "treatment" framing typically reflects patients researching their treatment plan options — often after antihistamines and intranasal steroids have proven insufficient.
Indications: allergic rhinitis/conjunctivitis, allergic asthma, Hymenoptera venom hypersensitivity (Cox 2011 PP3). Not first-line for food allergy or chronic urticaria. For chronic spontaneous urticaria, the FDA-approved targeted therapy is omalizumab (Xolair), an anti-IgE monoclonal antibody approved in 2014 — not SCIT. For food allergy, oral immunotherapy (OIT) and omalizumab (FDA-approved February 16, 2024 for multi-food allergy prevention, Wood RA et al., NEJM 2024;390:889-899, DOI 10.1056/NEJMoa2312382) are the current options — Palforzia (peanut OIT, FDA-approved 2020) is being commercially discontinued as of July 31, 2026.
Curex pairs at-home IgE testing with board-certified allergist review to determine which allergens are driving symptoms — the prerequisite diagnostic step before any allergy-shot treatment plan is built.
Treatment structure: build-up phase consists of approximately 24-28 weekly injections to reach maintenance dose (some patients on cluster protocols can complete build-up in 4-8 weeks with multiple injections per visit per Tabar AI et al., JACI 2005). Maintenance phase involves injections every 2-4 weeks for 3-5 years. Anatomical site: subcutaneous, upper outer arm posterolateral to the deltoid, alternating arms, 26-27G ½-inch needle (Cox 2011 PP3, Summary Statements 13-14). Mandatory 30-minute observation after each injection (Summary Statement 32; ~70% of severe reactions begin within this window).
Evidence summary: - Seasonal AR symptom SMD: −0.73 (95% CI −0.97 to −0.50) vs placebo (Calderón MA et al., Cochrane 2007, DOI 10.1002/14651858.CD001936.pub2; 51 RCTs, 2,871 patients) - Seasonal AR medication SMD: −0.57 (95% CI −0.82 to −0.33) vs placebo (Calderón 2007) - Asthma: NNT 3 to prevent one patient's asthma deterioration (Abramson MJ et al., Cochrane 2010, DOI 10.1002/14651858.CD001186.pub2; 88 SCIT trials) - VIT: 2.7% subsequent systemic sting reaction treated vs 39.8% untreated (Boyle RJ et al., Cochrane 2012, PMID 23076950) - Durability: ≥3-year post-treatment remission after 3-4 year course (Durham SR et al., NEJM 1999;341:468-475, DOI 10.1056/NEJM199908123410702) - Safety: 0.1% systemic-reaction rate per injection visit (Epstein TG et al., Ann Allergy Asthma Immunol PMID 23535092/24607043); ~1 fatality per 2.5M injections long-run (Bernstein DI et al., JACI 2004 12-year survey) - Cost-effectiveness: SCIT cost-effective vs pharmacotherapy from ~6 years after initiation (Cox L, Murphey A, Hankin C, Immunol Allergy Clin North Am 2020;40[1]:69-85, PMID 31761122)
Dropout reality: Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957-965, DOI 10.1080/03007995.2021.1903848) found 23.9% of immunotherapy patients never returned for their first injection, and only 43.9% reached maintenance in a large commercial claims database (n=103,207). The access and adherence burden is real.
Curex's At-Home Allergy Shot Kit (SCIT) at $129/month addresses both barriers directly: the personalized serum is sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist, and self-administered as one weekly subcutaneous shot at home. A prescribed epinephrine auto-injector is confirmed on-hand before the first injection, the first dose and every dose escalation are supervised live over Zoom, and gradual week-by-week escalation mirrors the same protocol used in clinics — making at-home maintenance possible for eligible patients without the 39-visit Year 1 clinic schedule.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
SCIT treatment proceeds in two main phases followed by a sustained post-treatment benefit period. The build-up schedule can be conventional, cluster, or rush — each with different time/risk tradeoffs.
Injections begin at the lowest dilution and escalate in concentration and volume at each visit, targeting the maintenance dose. Conventional build-up: ~24-28 weekly visits (Cox 2011 PP3). Cluster build-up: 4-8 weeks with multiple injections per visit separated by 20-30 minutes (Tabar AI et al., JACI 2005). Rush: 1-3 days, multiple injections per day under close supervision (Bernstein DI et al., JACI 2008 — 5-15% systemic-reaction rate, primarily used for VIT or select research protocols).
Once maintenance dose is reached, injection frequency drops to every 2-4 weeks. Most patients notice meaningful symptom improvement within the first year of maintenance. Missing maintenance doses may require dose adjustment per the prescribing allergist's protocol. Most patients make 12-25 clinic visits per year during maintenance.
Standard recommendation is to complete 3-5 years of maintenance before discussing discontinuation (Cox 2011 PP3). Durham SR et al. (NEJM 1999;341:468-475) showed 3-4 year grass SCIT produced sustained remission for at least 3 further years post-discontinuation. Relapse ranges from ~0% (grass pollen) to ~55% (dust mite) over 5 years (Cox & Cohn 2007). Re-initiation is possible if relapse occurs.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Is allergy shots treatment right for me?
Allergy shots are most appropriate for patients with IgE-mediated allergic disease — confirmed by skin or blood testing — whose symptoms are not adequately controlled by pharmacotherapy, or who want to reduce long-term medication dependence. Indications include allergic rhinitis, allergic conjunctivitis, allergic asthma (when controlled), and Hymenoptera venom hypersensitivity (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). Contraindications include uncontrolled asthma, beta-blocker use, severe cardiovascular disease, and pregnancy initiation. The practical assessment involves symptom severity, allergen-testing results, patient lifestyle (can weekly visits be accommodated?), and cost-insurance picture. A board-certified allergist is the appropriate person to make the candidacy assessment after reviewing your history and testing results.
How long does allergy shots treatment take?
Allergy shots treatment spans 3-5 years total — a build-up phase of approximately 24-28 weekly injections to reach maintenance dose, then a maintenance phase of monthly injections for 3-5 years (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). Year 1 involves approximately 39 in-person visits. Cluster build-up protocols (Tabar AI et al., JACI 2005) can compress build-up to 4-8 weeks with multiple injections per visit, reducing Year 1 visit count but increasing per-visit time. After completing the full course, the disease-modifying benefit — sustained immune tolerance — persists for years to a decade-plus post-treatment (Durham SR et al., NEJM 1999). The upfront time investment of 3-5 years must be weighed against decades of reduced or eliminated allergy symptoms.
What is the success rate of allergy shots treatment?
Clinical trial data suggests 50-80% of patients with allergic rhinitis achieve clinically meaningful improvement on SCIT (Cox 2011 PP3). The Cochrane seasonal AR meta-analysis (Calderón 2007, 51 RCTs) found symptom SMD −0.73 versus placebo — a clinically meaningful effect comparable to or better than pharmacotherapy. For Hymenoptera venom allergy, the success rate is higher: >95% prevention of systemic sting reactions (Golden DBK et al., JACI 2005; Boyle 2012 Cochrane: 2.7% vs 39.8% untreated). In real-world data, only 43.9% of immunotherapy patients reached maintenance (Tkacz JP et al., Curr Med Res Opin 2021), reflecting the access and adherence gap — not all patients who would benefit complete the course.
Does allergy shots treatment work for chronic hives?
No — subcutaneous immunotherapy (SCIT) is not indicated for chronic spontaneous urticaria (CSU, chronic hives). Cox 2011 PP3 lists chronic urticaria as a non-indication for SCIT. The FDA-approved targeted therapy for CSU in patients ≥12 years who remain symptomatic on H1-antihistamines is omalizumab (Xolair), approved in 2014. The treatment pathway for CSU is: (1) second-generation H1 antihistamines at standard dose; (2) up-dose H1 antihistamines up to 4× standard; (3) omalizumab (Xolair) if symptoms persist. The only exception is urticaria from Hymenoptera (bee/wasp) sting anaphylaxis — for that specific scenario, venom immunotherapy (VIT) IS indicated and highly effective (Cochrane Boyle 2012: 2.7% vs 39.8% subsequent sting reaction).
Does allergy shots treatment work for food allergies?
Subcutaneous immunotherapy (SCIT) is NOT standard of care for food allergies. The historical reason: a 1992 peanut SCIT trial by Oppenheimer et al. produced fatalities and was abandoned. The current standard approach for IgE-mediated food allergy is oral immunotherapy (OIT) through specialized food-allergy centers, or avoidance. For multi-food allergy, omalizumab (Xolair) received FDA approval on February 16, 2024, for reducing reaction severity during accidental exposure (OUtMATCH trial: Wood RA et al., NEJM 2024;390:889-899, DOI 10.1056/NEJMoa2312382 — 67% protection vs 7% placebo). Palforzia (peanut OIT powder, FDA-approved 2020) is being commercially discontinued as of July 31, 2026.
What are the alternatives to allergy shots treatment?
The main disease-modifying alternatives to SCIT are: (1) Sublingual immunotherapy (SLIT) drops — custom allergen formulations prescribed by a board-certified allergist, taken daily as under-the-tongue drops at home; strong European evidence base comparable to SCIT for studied allergens; no needles or in-office visits after initial evaluation. (2) FDA-approved SLIT tablets — Grastek (grass), Oralair (5-grass mix), Ragwitek (ragweed), Odactra (dust mite) — approved for specific single-allergen sensitizations, first dose given in-office with observation. (3) Xolair (omalizumab) — for moderate-severe asthma, CSU, and multi-food allergy; biologic mechanism different from immunotherapy. (4) Pharmacotherapy — antihistamines and intranasal corticosteroids; effective for symptom control but not disease-modifying. The choice depends on allergen profile, lifestyle, and patient preference.
What is the dropout rate for allergy shots treatment?
Allergy shot dropout is a recognized clinical problem. Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957-965, DOI 10.1080/03007995.2021.1903848) analyzed the IBM MarketScan database (n=103,207 allergy immunotherapy patients, 2014-2017) and found 23.9% never returned for their first injection after the initial consultation, and only 43.9% ultimately reached the maintenance phase. Dropout is driven by multiple factors: geographic access (81.5% of US counties have zero allergists per Wu I et al., AAAAI 2019), time burden (39+ in-office visits in Year 1), insurance navigation complexity, and cost concerns — particularly HOPD facility fee exposure. For patients who cannot sustain the traditional in-clinic injection schedule, Curex's At-Home Allergy Shot Kit makes SCIT self-administered — one weekly subcutaneous shot at home for $129/month, with Zoom-supervised first dose and every dose escalation, a prescribed epinephrine auto-injector confirmed on-hand, and board-certified allergist oversight throughout the course.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreShot for Pollen Allergy: SCIT Guide | Curex
Shot for pollen allergy: SCIT with Cochrane SMD −0.73 (51 RCTs). Durham 1999: 3-yr grass course → 3+ yr remission. 7 FDA-standardized extracts listed.
Read moreAllergy Shots for Hives: SCIT vs Xolair | Curex Guide
Allergy shots (SCIT) not first-line for chronic hives — Xolair is (FDA 2014). Exception: venom shots (VIT) for Hymenoptera-triggered hives. Full guide.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreAllergy Shot Test: Skin Testing vs SCIT | Curex Guide
Allergy shot test = skin prick testing (CPT 95004, diagnostic). NOT the same as a SCIT shot (CPT 95117). HOPD test panels billed $24,400–$48,329.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.